AnaptysBio
ANAB
213 hedge funds and large institutions have $2.05B invested in AnaptysBio in 2026 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 73 increasing their positions, 65 reducing their positions, and 37 closing their positions.
32% more capital invested
Capital invested by funds: $1.55B → $2.05B (+$499M)
24% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 37
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
12% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 65
5.27% more ownership
Funds ownership: 98.27% → 103.54% (+5.3%)
2% more funds holding
Funds holding: 208 → 213 (+5)
47% less call options, than puts
Call options by funds: $3.48M | Put options by funds: $6.58M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$22.6M |
| 2 |
Millennium Management
New York
|
+$20.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$17.8M |
| 4 |
ACA
Apis Capital Advisors
New York
|
+$15.7M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$44.7M |
| 2 |
SAM
Synergy Asset Management
Vancouver,
Washington
|
-$17.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.1M |
| 4 |
Two Sigma Investments
New York
|
-$12.2M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$6.9M |
ANAB Hedge Fund Activity: Q2 2026 in Review
213 of the 8,303 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q2 2026, worth a combined $2.05B — up 32% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ANAB positions and 37 closed out — a net gain of 9 holders — while 73 added to existing stakes and 65 trimmed.
The largest buyer was Woodline Partners, adding an estimated $22.6M. The largest seller was Morgan Stanley, cutting an estimated $44.7M.
- 213 institutional investors held AnaptysBio (ANAB) as of Q2 2026, up from 208 in Q1 2026.
- Funds reported $2.05B of AnaptysBio stock for Q2 2026, up 32% quarter-over-quarter.
- 46 funds opened new AnaptysBio positions in Q2 2026 and 37 closed out, a net change of +9 holders.
- The largest AnaptysBio buyer in Q2 2026 was Woodline Partners, an estimated $22.6M added.
- The largest AnaptysBio seller in Q2 2026 was Morgan Stanley, an estimated $44.7M sold.
Based on aggregated 13F filings for Q2 2026.